OsteoGeneX is developing a first in class bone building small molecule against the validated target Sclerostin. OsteoGeneX possesses both near term accelerated clinical development opportunities, combined with proprietary approaches to developing first-in-class novel therapeutics.
| Website | https://www.osteogenexinc.com |
| Employees | 9 (5 on RocketReach) |
| Address | 11235 Mastin St, Overland Park, Kansas 66210, US |
| Industry | Biotechnology Research |
Looking for a particular OsteoGeneX, Inc employee's phone or email?
5 people are employed at OsteoGeneX, Inc.
OsteoGeneX, Inc is based in Overland Park, Kansas.